Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production

Gene Therapy

Volumn 7, Issue 1, 2000, Pages 35-42

  Weijtens, M E M ^a   Hart, E H ^a   Bolhuis, R L H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chimeric receptor density; Effector cell function; Tumor cell antigen density

Indexed keywords

FC RECEPTOR; GAMMA INTERFERON; LYMPHOKINE; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE CONSTRUCT; GENE THERAPY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOGENETICS; KIDNEY CARCINOMA; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0033959105     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301051     Document Type: Article

References (38)

1. Bolhuis RLH et al. Cell-cell interactions. Clin Immunol Allergy 1986; 6: 29-90.
2. Janeway CA Jr et al. Signals and signs for lymphocyte responses. Cell 1994; 76: 275-285.
3. Perez P et al. Specific targeting of cytotoxic T cells by anti-CD3 linked to anti-target antibody. Nature 1985; 316: 354-356.
4. Bolhuis RLH et al. Adoptive immunotherapy of ovarian carcinoma with bsmAb-targeted lymphocytes: a multicenter study. Int J Cancer 1992; 7: 78-81.
5. Kanagawa O et al. Requirement of the T cell antigen receptor occupancy for the target cell lysis by cytolytic T lymphocytes. Int Immunol 1989; 1: 565-569.
6. Braakman E et al. ICAM-melanoma cells are relatively resistant to CD3-mediated T cell lysis. Int J Cancer 1990; 46: 475-480.
7. Goedegebuure PS et al. Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis. Int Immunol 1990; 2: 1213-1220.
8. Blank-Voorthuis CJAC et al. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J Immunol 1993; 151: 2904-2914.
9. Valitutti S et al. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med 1997; 185: 1859-1864.
10. Valitutti S et al. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996; 183: 1917-1921.
11. Blichfelt E et al. Dual T cell receptor T cells have a decreased sensitivity to physiological ligands due to reduced density of each T cell receptor. Eur J Immunol 1996; 26: 2876-2884.
12. Hemmer B et al. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 1998; 160: 5807-5814.
13. Munthe LA et al. T cells with two TCR-beta chains and reactivity to both MHC/idiotypic peptide and superantigen. Cell Immunol 1996; 170: 283-290.
14. Viola A et al. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104-106.
15. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-182.
16. Eshhar Z et al. Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. Br J Cancer 1990; 62: 27-29.
17. Eshhar Z et al. The T-body approach: potential for cancer immunotherapy. Semin Immunopathol 1996; 18: 199-209.
18. Bolhuis RLH. Genetic re-targeting of T lymphocyte specificity. Gene Therapy 1998; 5: 1153-1155.
19. Hwu P et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178: 361-366.
20. + T lymphocytes armed with universal T cell receptors. Blood 1994; 84: 2878-2889.
21. Weijtens MEM et al. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle their lytic capacity. J Immunol 1996; 157: 836-843.
22. Weijtens MEM et al. Chimeric scFv/gamma receptor-mediated T cell lysis of tumor cells is co-regulated by adhesion and accessory molecules. Int J Cancer 1998; 77: 181-187.
23. Weijtens MEM et al. A retroviral vector system STITCH in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Therapy 1998; 5: 1195-1203.
24. Eshhar Z et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
25. Hwu P et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995; 55: 3369-3375.
26. Hekele A et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int J Cancer 1996; 68: 232-238.
27. Altenschmidt U et al. Adoptive transfer of in vitro targeted, activated T lymphocytes results in total tumor regression. J Immunol 1997; 159: 5509-5515.
28. Oosterwijk E et al. The use of monoclonal antibody G250 in the therapy of renal cell carcinoma. Semin Oncol 1995; 22: 34-41.
29. van Dijk J et al. Induction of tumor cell lysis by bi-specific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen. Int J Cancer 1989; 43: 344-349.
30. Valitutti S et al. Serial triggering of many T-cell receptors by a few peptide-MHC complexes, Nature 1995; 375: 148-151.
31. Rotnes JS et al. Ca2+ mobilization in physiologically stimulated single T cells gradually increases with peptide concentration (analog signaling). Eur J Immunol 1994; 24: 851-858.
32. Alvarez-Vallina L et al. Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther 1999; 10: 559-563.
33. Fleuren GJ et al. Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 1995; 145: 97-122.
34. Uemura H et al. Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer 1994; 56: 609-614.
35. Miller AD et al. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-990.
36. Braakman E et al. Expression of CD45-isoforms by fresh and activated human gamma delta T lymphocytes and natural killer cells. Int Immunol 1991; 3: 691-697.
37. van de Griend RJ et al. Rapid expansion of allospecific cytotoxic T cell clones using nonspecific feeder cell lines without further addition of exogenous IL-2. Transplantation 1984; 38: 401-406.
38. van de Griend RJ et al. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J Immunol Meth 1984; 66: 285-298.